NCT07710768 UBT-251 Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07710768 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 3 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07710768 is a hot trial to watch
Obesity is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07710768 is notable because it evaluates UBT-251 in a Phase 1 design sponsored by Novo Nordisk A/S. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07710768 |
| Official title | A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight |
| Phase / status | Phase 1 / Not yet recruiting |
| Intervention | UBT-251 |
| Sponsor | Novo Nordisk A/S |
| Geography | United States |
| Enrollment | [object Object] |
| Primary endpoint | AUC0-∞,s-warfarin: The area under the plasma s-warfarin concentration-time curve extrapolated to infinity after single dose |
| Endpoint time frame | From pre-dose on Day 1 up to 156 days |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like midazolam, caffeine and warfarin in participants living with overweight or obesity.
Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Sequential Assignment. Planned enrollment of [object Object] participants across United States shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- AUC0-∞,s-warfarin: The area under the plasma s-warfarin concentration-time curve extrapolated to infinity after single dose (From pre-dose on Day 1 up to 156 days) — Measured in nanogram hour per millilitre (ng\*h/mL).
- AUC0-∞,caffeine : The area under the plasma caffeine concentration-time curve extrapolated to infinity after single dose (From pre-dose on Day 1 up to 156 days) — Measured in ng\*h/mL.
- AUC0-∞,midazolam: The area under the midazolam concentration-time curve extrapolated to infinity after single dose (From pre-dose on Day 1 up to 156 days) — Measured in ng\*h/mL.
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: UBT-251 is indexed as Synthetic peptide, with target GCGR x GIPR x GLP-1R, mechanism GCGR agonists, GIPR agonists, GLP-1R agonists, and global highest development status Phase 3.
Company & Deal Intelligence MCP profile: Novo Nordisk A/S is resolved to a normalized organization record in Denmark. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07710768 provides a focused lens on Obesity development. Its value will be determined by whether UBT-251 can convert the current Phase 1 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
